Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.39 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.39 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.39 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.39 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.39 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.39 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.39 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.39 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.39 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21180483 | 0.89 | ACKR3 (0.45) | CES2CES1CTSSCTSKEPHX2 | |
| SCHEMBL29483416 | 0.89 | ACKR3 (0.45) | CES2CES1CTSSCTSKEPHX2 | |
| SCHEMBL12321082 | 0.85 | BRD4 (0.39) | CTSSCTSKMAPTEPHX2BRD4 | |
| SCHEMBL17820830 | 0.84 | CA1 (0.44) | CES2CES1BRD4 | |
| SCHEMBL29462507 | 0.84 | CA1 (0.44) | CES2CES1BRD4 | |
| SCHEMBL28939126 | 0.83 | TDP1 (0.46) | BRD4 | |
| SCHEMBL25675005 | 0.83 | EGLN2 (0.42) | GPR119EGFRAURKBCTSSCTSK | |
| SCHEMBL30975794 | 0.83 | EGLN2 (0.42) | GPR119EGFRAURKBCTSSCTSK | |
| SCHEMBL29867824 | 0.82 | CES2 (0.38) | CES2CES1GPR119CTSSCTSK | |
| SCHEMBL16687897 | 0.82 | SERPINE1 (0.41) | EGFRAURKBMAPTEPHX2KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105392772-B | Preparation method of key intermediate of augustine | 意大利合成制造有限公司 | 2017-09-15 | — | — | CN | disclosed |
| US-9481680-B2 | Process for the preparation of key intermediates of omarigliptin | F.I.S.—FABBRICA ITALIANA SINTETICI S.P.A (IT) | 2016-11-01 | — | — | US | disclosed |
| US-9481680-B2 | Process for the preparation of key intermediates of omarigliptin | F.I.S.—FABBRICA ITALIANA SINTETICI S.P.A (IT) | 2016-11-01 | — | — | US | disclosed |
| US-9481680-B2 | Process for the preparation of key intermediates of omarigliptin | F.I.S.—FABBRICA ITALIANA SINTETICI S.P.A (IT) | 2016-11-01 | — | — | US | disclosed |
| US-20160200727-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES OF OMARIGLIPTIN | F.I.S.- FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2016-07-14 | — | — | US | disclosed |
| US-20160200727-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES OF OMARIGLIPTIN | F.I.S.- FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2016-07-14 | — | — | US | disclosed |
| US-20160200727-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES OF OMARIGLIPTIN | F.I.S.- FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2016-07-14 | — | — | US | disclosed |
| EP-2997008-B1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES OF OMARIGLIPTIN | ITALIANA SINT SPA (IT) | 2016-06-29 | — | — | EP | disclosed |
| EP-2997008-B1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES OF OMARIGLIPTIN | ITALIANA SINT SPA (IT) | 2016-06-29 | — | — | EP | disclosed |
| EP-2997008-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES OF OMARIGLIPTIN | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2016-03-23 | — | — | EP | disclosed |
| CN-105392772-A | Preparation method of key intermediate of augustine | FIS FABBRICA ITALIANA SINTETICI SPA | 2016-03-09 | — | — | CN | disclosed |
| WO-2015139859-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES OF OMARIGLIPTIN | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015139859-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES OF OMARIGLIPTIN | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2015-09-24 | — | — | WO | disclosed |
| US-8796460-B2 | Compounds for inhibiting KSP kinesin activity | Mercky Sharp & Dohme Corp. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120070370-A1 | SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-03-22 | — | — | US | disclosed |
| US-20110171172-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME CORP. | 2011-07-14 | — | — | US | disclosed |
| US-20110123435-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME LLC | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200727-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES OF OMARIGLIPTIN | SI, OSTC, VIP | CES2 3492/4885CES1 811/4885GPR119 428/4885 |
| US-20120070370-A1 | SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS | KIF2C, SKP1, KIF5B | CES2 3632/4885CES1 1767/4885GPR119 3462/4885 |
| US-20110123435-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | KIF5B, KIF2C, KIFC1 | CES2 3392/4885CES1 2203/4885GPR119 3188/4885 |
| US-20110171172-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | KIF5B, KIF2C, KIFC1 | CES2 3579/4885CES1 2491/4885GPR119 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.